Systematic review with meta‐analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases-Reference-Cited by-同舟云学术

Systematic review with meta‐analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases

Published:2022-02-09 Issue:7 Volume:55 Page:764-777
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Yang Hongsheng¹²^ORCID,Li Bingyang¹²,Guo Qin¹²,Tang Jian¹²,Peng Bo¹²,Ding Ni¹²,Li Miao¹²,Yang Qingfang¹²,Huang Zicheng¹²,Diao Na¹²,Zhu Xia¹²,Deng Jun¹²,Guo Huili¹²,Hu Pinjin¹²,Chao Kang¹²,Gao Xiang¹²^ORCID

Affiliation:

1. Department of Gastroenterology, the Sixth Affiliated Hospital Sun Yat‐sen University Guangzhou P. R. China

2. Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, the Sixth Affiliated Hospital Sun Yat‐sen University Guangzhou P. R. China

Funder

China Postdoctoral Science Foundation

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16802

Reference41 articles.

1. Novel therapeutic targets for inflammatory bowel disease

2. Biologic agents for IBD: practical insights